Jefferies downgrades Moonlake Immunotherapeutics stock rating to Hold on disappointing trial results

Moonlake Immunotherapeutics (NASDAQ:MLTX) shares plummeted 90% to $6.19 after reporting mixed Phase III trial results for its hidradenitis suppurativa drug, sonelokimab, with one trial failing statistical significance and the other showing lower-than-expected efficacy. Jefferies responded by downgrading MLTX from Buy to Hold and slashing its price target from $65 to $8, citing reduced probability of regulatory approval and diminished commercial and M&A opportunity. Conversely, Wedbush, Guggenheim, and Clear Street maintained their Outperform/Buy ratings with significantly higher price targets, reflecting a divergence in analyst outlooks despite the clinical setbacks.

Analysis

Moonlake Immunotherapeutics (MLTX) experienced a catastrophic 90% decline in its stock price, falling to $6.19 from $56.38, following the release of mixed Phase III trial results for its lead drug candidate, sonelokimab (SLK). The VELA study for hidradenitis suppurativa yielded disappointing outcomes, with one trial failing to achieve statistical significance and the other, while meeting its primary endpoint, demonstrating a placebo-adjusted efficacy of only 17%, below the 20-26% expectation. This clinical setback has created a sharp divergence in analyst sentiment. Jefferies downgraded the stock from Buy to Hold and slashed its price target from $65.00 to $8.00, citing a lower probability of regulatory approval, diminished commercial opportunity, and reduced M&A value. In stark contrast, Wedbush, Guggenheim, and Clear Street reiterated their Buy/Outperform ratings with price targets ranging from $80.00 to $108.00, signaling a belief in the drug's long-term potential despite the trial's shortcomings. The market's severe reaction aligns with Jefferies' bearish assessment, reflecting deep investor disappointment and a fundamental reassessment of SLK's future viability.

Key Decisions for Investors

• Given the 90% stock collapse and Jefferies' assessment of diminished commercial and M&A potential, risk-averse investors should recognize that the market is pricing in a high probability of failure for sonelokimab.
• The extreme divergence between the current stock price near $6 and bullish analyst price targets of $80-$108 presents a high-risk, high-reward scenario for contrarian investors willing to bet against the prevailing market sentiment.
• All investors should closely monitor upcoming trial data and regulatory guidance, as these will be the definitive catalysts to either validate the bearish market reaction or support the contrarian bull case from firms like Wedbush and Guggenheim.